# Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

> **NCT05147220** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 1001 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Remibrutinib
- **DRUG:** Teriflunomide

## Key facts

- **NCT ID:** NCT05147220
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-16
- **Primary completion:** 2026-04-30
- **Final completion:** 2030-10-30
- **Target enrollment:** 1001 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05147220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05147220, "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05147220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*